{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:42:34Z","timestamp":1789688554214,"version":"4.0.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["SBGJ202402041"],"award-info":[{"award-number":["SBGJ202402041"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bispecific antibodies (BsAbs) are cutting-edge immunotherapy agents that can bind two distinct antigens or epitopes simultaneously. They hold significant potential in targeting leukemic cell markers and activating immune cells like T cells or NK cells to eliminate malignant cells. BsAb treatments showed encouraging outcomes for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In relapsed\/refractory (R\/R) ALL, BsAbs improved overall survival (OS) and achieved measurable residual disease (MRD) negativity in most patients. Blinatumomab plus standard chemotherapy or in combination with other treatments, such as Mini-Hyper-CVD and Inotuzumab Ozogamicin, improved disease-free survival (DFS) in B-ALL. In AML and related conditions, novel BsAbs like AFM28 (CD123xCD16A) and Vibecotamab (CD123xCD3) showed promising efficacy in heavily pretreated R\/R AML and in MDS\/CMML following the failure of treatment with hypomethylating agents (HMA). The meeting underscored the transformative potential of BsAbs, especially in ALL-focused trials, with ongoing research aiming to evaluate their safety and efficacy in broader patient populations and combination regimens. This summary highlights the latest progress in BsAb-based immunotherapy presented at the ASH 2024 meeting, held from December 7\u201310 in San Diego, California.<\/jats:p>","DOI":"10.3389\/fonc.2025.1566202","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:39:21Z","timestamp":1744191561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Bispecific antibodies in immunotherapy for acute leukemia: latest updates from the 66th annual meeting of the American society of hematology, 2024"],"prefix":"10.3389","volume":"15","author":[{"given":"Weijie","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhou","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","volume":"42","author":"Hodder","year":"2024","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2333793","article-title":"Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting","volume":"24","author":"Han","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/blood-2024-205662","article-title":"Single-agent subcutaneous blinatumomab for advanced B-cell acute lymphoblastic leukemia: long-term follow-up from a phase 1b dose expansion cohort","volume":"144","author":"Jabbour","year":"2024","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/blood-2024-210501","article-title":"Updated results of the combination of mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab in patients with relapsed\/refractory B-cell ALL","volume":"144","author":"Habib","year":"2024","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1431.1","DOI":"10.1182\/blood-2024-212144","article-title":"Phase II study of pedi-crib: mini-hyper-CVD with condensed rituximab, inotuzumab ozogamicin and blinatumomab (cRIB) for relapsed therapy for pediatric patients with B-cell lineage acute lymphocytic leukemia","volume":"144","author":"McCall","year":"2024","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1182\/blood-2024-208854","article-title":"Updated results from a phase II study hyper-CVAD, with or without inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-cell acute lymphoblastic leukemia","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1182\/blood-2024-200685","article-title":"ABC regimen: combination of 3rd generation TKI olverembatinib, blinatumomab and chidamide for older new diagnosed ph-positive ALL patients","volume":"144","author":"Chen","year":"2024","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207450","article-title":"Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk pediatric B-acute lymphoblastic leukemia: results from the randomized children\u2019s oncology group study AALL1731","volume":"144","author":"Rau","year":"2024","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood-2024-207892","article-title":"Efficacy and toxicity of frontline ponatinib plus blinatumomab for adult ph+ ALL patients of all ages. Intermediate analysis of the gimema ALL2820","volume":"144","author":"Chiaretti","year":"2024","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1182\/blood-2024-194356","article-title":"Engaging innate immunity by AFM28, an innate cell engager (ICE\u00ae) targeting CD123-positive leukemic cells in patients with relapsed\/refractory acute myeloid leukemia: safety and efficacy results of a first-in-human phase 1 study","volume":"144","author":"Montesinos","year":"2024","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2024-208684","article-title":"Updated results from a phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1566202\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:39:21Z","timestamp":1744191561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1566202\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":11,"alternative-id":["10.3389\/fonc.2025.1566202"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1566202","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"article-number":"1566202"}}